Treatment of CML cells with RITA, CPI-203, the combination thereof and nilotinib.
Ontology highlight
ABSTRACT: CML CD34+ cells were treated with RITA, CPI-203, the combination thereof and nilotinib.
PROVIDER: PRJEB9942 | ENA |
REPOSITORIES: ENA
ACCESS DATA